Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.
Celsius Therapeutics has raised $83.0M in total funding. The most recent round was Series B. The last funding was announced in March 2022.
Celsius Therapeutics's investors include Catalio Capital Management, Casdin Capital, S32, Google Ventures, Third Rock Ventures.
Celsius Therapeutics is headquartered in Cambridge, United States.
Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.
Celsius Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Celsius Therapeutics — Funding & Investors." VCBacked, March 24, 2022, https://www.vcbacked.co/company/celsius-therapeutics. Accessed August 15, 2026.
VCBacked. (2022). Celsius Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/celsius-therapeutics
{{cite web |title=Celsius Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/celsius-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated